Related Experiment Video
Updated: Mar 10, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic
Lei Zhu1, Charles Staley1, David Kooby1
1Department of Surgery, Emory University School of Medicine, Atlanta, GA 30322, United States.
Abstract:
Pancreatic cancer remains one of the major causes of cancer-related mortality. The majority of pancreatic cancer patients are diagnosed at the advanced stage with unresectable and drug resistant tumors. The new treatments with the combination of chemotherapy, molecular targeted therapy, and immunotherapy have shown modest effects on therapeutic efficacy and survival of the patients. Therefore, there is an urgent need to develop effective therapeutic approaches targeting highly heterogeneous pancreatic cancer cells and tumor microenvironments. Recent advances in biomarker targeted cancer therapy and image-guided drug delivery and monitoring treatment response using multifunctional nanoparticles, also referred to as theranostic nanoparticles, offer a new opportunity of effective detection and treatment of pancreatic cancer. Increasing evidence from preclinical studies has shown the potential of applications of theranostic nanoparticles for designing precision oncology approaches for pancreatic cancer therapy. In this review, we provide an update on the current understanding and strategies for the development of targeted therapy for pancreatic cancer using nanoparticle drug carriers. We address issues concerning drug delivery barriers in stroma rich pancreatic cancer and the potential approaches to improve drug delivery efficiency, therapeutic responses and tumor imaging. Research results presented in this review suggest the development of an integrated therapy protocol through image-guided and targeted drug delivery and therapeutic effect monitoring as a promising precision oncology strategy for pancreatic cancer treatment.
Insights
Theranostic nanoparticles offer a promising approach for pancreatic cancer treatment by enabling targeted drug delivery and monitoring. This strategy aims to overcome drug resistance and improve patient survival in precision oncology.
Area of Science:
- Nanomedicine
- Oncology
- Biotechnology
Background:
- Pancreatic cancer is a leading cause of cancer mortality, often diagnosed at advanced, untreatable stages.
- Current treatments combining chemotherapy, targeted therapy, and immunotherapy show limited efficacy due to tumor heterogeneity and drug resistance.
- There is a critical need for novel therapeutic strategies to effectively target pancreatic cancer cells and their microenvironments.
Purpose of the Study:
- To review the potential of theranostic nanoparticles for pancreatic cancer therapy.
- To discuss strategies for overcoming drug delivery barriers in the stroma-rich pancreatic tumor microenvironment.
- To highlight the integration of image-guided delivery, targeted therapy, and treatment response monitoring for precision oncology.
Main Methods:
- Review of preclinical studies on theranostic nanoparticle applications in pancreatic cancer.
- Analysis of challenges in drug delivery within the pancreatic tumor microenvironment.
- Exploration of approaches to enhance drug delivery efficiency, therapeutic response, and tumor imaging.
Main Results:
- Theranostic nanoparticles show potential for biomarker-targeted cancer therapy and image-guided drug delivery.
- Multifunctional nanoparticles can aid in the detection, treatment, and monitoring of pancreatic cancer.
- Preclinical evidence supports the use of theranostic nanoparticles in designing precision oncology approaches.
Conclusions:
- Theranostic nanoparticles represent a promising avenue for developing effective pancreatic cancer treatments.
- An integrated therapy protocol involving image-guided, targeted drug delivery and response monitoring is a key strategy for precision oncology.
- Further research into nanoparticle-based approaches is crucial for improving therapeutic efficacy and patient survival.
